Psychedelic and Novel CNS Drug Development

Supporting Psychedelic Drug Formulation Development.

Speak to our experts

The central nervous system (CNS) drug development landscape is evolving rapidly, with growing investment in psychedelic compounds and novel therapeutics targeting a range of neurological and psychiatric conditions. As these programmes advance through development, sponsors require experienced partners capable of navigating complex formulation challenges, regulatory requirements and specialised manufacturing considerations.

At Upperton, we support the development and manufacture of drug products containing psychedelic compounds and novel CNS-active molecules. Combining formulation expertise with integrated analytical and manufacturing capabilities, we help pharmaceutical and biotechnology companies progress innovative therapies from early development through to clinical supply.

Whether your programme involves oral solid dosage forms, nasal delivery, pulmonary products or other specialist formulations, our scientific teams work collaboratively to develop robust drug products that support clinical success.

Supporting the Next Generation of CNS Therapies

Formulation Expertise for Complex CNS Programmes

Novel CNS therapies often present unique development challenges, including low-dose formulations, solubility limitations, stability considerations and patient-centric delivery requirements.

Formulation development
Pre-formulation studies
Analytical development and testing
Process development
Clinical trial supply manufacturing
Technology transfer support

Our experience across multiple dosage forms enables us to design development strategies tailored to the specific requirements of each molecule and target patient population.

Psychedelic Drug Develpoment

Sterile-finish isolator image with scientist working on biotech project.

Supporting Psychedelic Drug Development

As interest in psychedelic-based therapies continues to grow, drug developers require partners with the capability to support clinical development programmes efficiently and compliantly.

Upperton supports the development and manufacture of drug products containing psychedelic compounds, helping clients navigate the challenges associated with bringing these innovative therapies into clinical studies. Through integrated development, analytical and manufacturing services, we provide a streamlined pathway from formulation concept through to clinical supply.

Contact us to discuss your molecule in more detail

Speak to our team

Why Upperton

At Upperton, we specialise in the formulation and development of complex molecules, supporting a wide range of advanced drug delivery systems.

Our expertise spans:

By combining scientific excellence with practical development expertise, we help overcome the challenges of complex drug products and accelerate their path to clinic and market.

partnership

Why Partner with Upperton

We provide fully integrated services across every stage of drug product development:

Microscope and analysis equipment at the Upperton facility

One Site

Integrated, end-to-end capabilities delivered under one roof.

Upperton scientist examining a formulation flask

One Team

The same team from your early-stage development through to preparation for commercial launch.

Test tubes used in complex molecule formulation development

Complex Molecule Expertise:

Proven track record in solving formulation and delivery challenges.

Upperton senior leadership overseeing laboratory work

Executive Leadership on Every Project:

Direct access to experienced senior leadership for strategic oversight and decision-making.

Download Information Sheet

We provide fully integrated services across every stage of drug product development.

This field is for validation purposes and should be left unchanged.